We are live on ! Find out more
ATXS

Astria Therapeutics

Delisted

ATXS was delisted on the 22nd of January, 2026.

80 hedge funds and large institutions have $286M invested in Astria Therapeutics in 2023 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 35 increasing their positions, 16 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

188% more call options, than puts

Call options by funds: $345K | Put options by funds: $120K

150% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 8

119% more repeat investments, than reductions

Existing positions increased: 35 | Existing positions reduced: 16

100% more funds holding in top 10

Funds holding in top 10: 12 (+1)

67% more capital invested

Capital invested by funds: $171M → $286M (+$114M)

20.62% more ownership

Funds ownership: 81.96%102.58% (+21%)

18% more funds holding

Funds holding: 6880 (+12)

Holders
80
Holders Change
+12
Holders Change %
+17.65%
% of All Funds
1.17%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.03%
New
20
Increased
35
Reduced
16
Closed
8
Calls
$345K
Puts
$120K
Net Calls
+$225K
Net Calls Change
+$266K

ATXS Hedge Fund Activity: Q4 2023 in Review

80 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Astria Therapeutics (ATXS) for Q4 2023, worth a combined $286M — up 67% from $171M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new ATXS positions and 8 closed out — a net gain of 12 holders — while 35 added to existing stakes and 16 trimmed.

The largest buyer was VR Adviser, opening a new position worth an estimated $17.8M. The largest seller was Deep Track Capital, exiting entirely with an estimated $7.74M sold.

  • 80 institutional investors held Astria Therapeutics (ATXS) as of Q4 2023, up from 68 in Q3 2023.
  • Funds reported $286M of Astria Therapeutics stock for Q4 2023, up 67% quarter-over-quarter.
  • 20 funds opened new Astria Therapeutics positions in Q4 2023 and 8 closed out, a net change of +12 holders.
  • The largest Astria Therapeutics buyer in Q4 2023 was VR Adviser, an estimated $17.8M added.
  • The largest Astria Therapeutics seller in Q4 2023 was Deep Track Capital, an estimated $7.74M sold.

Based on aggregated 13F filings for Q4 2023.